Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database
Author(s):
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.
Video content above is prompted by the following question(s):
- How might conditions such as allergic rhinitis, anxiety, and asthma intersect with AD in terms of disease management and treatment response?
- Can you summarize the treatment patterns observed in this study before and after initiation of ruxolitinib cream, including the utilization of other topical and systemic therapies?
- Considering the baseline therapies used by patients prior to initiating ruxolitinib cream, does the distribution align with what you would expect in this patient population?
- Are there any specific patterns or trends in baseline therapy utilization that you find noteworthy or unexpected from this study?
Related Videos
Related Content
